What the research found

The relationship between body weight and type 2 diabetes risk isn't as straightforward as BMI suggests. Research from Newcastle University, referenced through Roy Taylor's work, proposes that individual variation in where the body stores fat—rather than total fat mass alone—determines metabolic health. The concept of a "personal fat threshold" suggests each person has a different capacity for safe fat storage; when this threshold is exceeded, excess fat accumulates in the liver and pancreas rather than subcutaneous tissue.

This ectopic fat deposition (the "Twin Cycle" hypothesis) is proposed as the mechanism driving insulin resistance and elevated blood glucose, independent of overall body composition. The implication is that pancreatic beta cells may enter a dysfunctional state rather than permanently die, potentially allowing recovery if the lipid overload is reduced. Weight loss in the range of 22–33 pounds has been associated with type 2 diabetes remission in research, with some improvements in liver fat and fasting glucose appearing relatively quickly after fat loss begins.

Why it matters for you

If you're tracking fasting glucose or HbA1c as a MyKine biomarker, understanding your individual metabolic threshold is more predictive than relying on BMI or total body fat percentage alone. Two users with identical body weight can have vastly different insulin sensitivity depending on hepatic and pancreatic fat content—factors that don't show up on a scale but do show up in your blood work and continuous glucose monitoring trends.

This framework reframes type 2 diabetes remission as achievable rather than inevitable decline. Rather than requiring extreme intervention, modest weight loss—in the 20–30 pound range—paired with lifestyle shifts may restore beta cell function. The episode mentions four practical micro-habits: a pre-meal food choice, a simple movement (seated calf raises), meal sequencing, and evening light exposure. These are modest enough to layer into existing routines without requiring complete protocol overhauls.

For users with normal BMI but elevated fasting glucose or insulin levels, this research validates that your labs reflect real metabolic stress that standard weight-based risk calculators miss. Conversely, if you're tracking improvements in liver enzymes or fasting glucose after modest fat loss, you may be observing beta cell recovery—a tangible sign that metabolic damage isn't permanent.

Caveats

  • The "personal fat threshold" and "Twin Cycle" model, while influential, remain mechanistic hypotheses rather than fully validated mechanisms
  • Weight loss figures (22–33 pounds) cited are described only as being "linked to" remission; effect sizes, study populations, and whether this represents average or threshold values are not specified
  • Timeline for improvements in liver fat and fasting glucose mentioned but not quantified
  • No detail on how to measure or identify your individual fat threshold outside of observing biomarker response
  • Limited specificity on the four micro-habits; their individual or combined evidence base is not discussed